ES2124545T3 - Azolidindionas como agentes antihiperglucemicos. - Google Patents

Azolidindionas como agentes antihiperglucemicos.

Info

Publication number
ES2124545T3
ES2124545T3 ES95916989T ES95916989T ES2124545T3 ES 2124545 T3 ES2124545 T3 ES 2124545T3 ES 95916989 T ES95916989 T ES 95916989T ES 95916989 T ES95916989 T ES 95916989T ES 2124545 T3 ES2124545 T3 ES 2124545T3
Authority
ES
Spain
Prior art keywords
image
azolidindionas
hyperglycemic agents
alkyl
hyperglycemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95916989T
Other languages
English (en)
Inventor
Michael Sotiorios Malamas
Iwan Gunawan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2124545T3 publication Critical patent/ES2124545T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

ESTA INVENCION SE REFIERE A NUEVOS COMPUESTOS QUE HAN DEMOSTRADO ACTIVIDAD ANTIHIPERGLICEMICA ORAL EN RATONES OB/OB Y DB/DB, MODELOS ANIMALES EN DIABETES MELLITUS NO INSULINODEPENDIENTES (NIDDM O DIABETES TIPO II). ESTOS COMPUESTOS TIENEN LA FORMULA (I), DONDE: R{SUP,1} ES ALQUILO C{SUB,1}-C{SUB,6}, CICLOALQUILO C{SUB,3}-C{SUB,8}, TIENILO, FURILO, PIRIDILO, (A) O (B) DONDE R{SUP,10} ES HIDROGENO, ALQUILO C{SUB,1}-C{SUB,6}, FLUORO, CLORO, BROMO, IODO, ALQUILOXI C{SUB,1}-C{SUB,6}, TRIFLUOROALQUILO O TRIFLUOROALCOXI; R{SUP,2} ES HIDROGENO O ALQUILO C{SUB,1}-C{SUB,6}; X ES O O S; N ES 0, 1, O 2; A ES (C) O (D); DONDE R{SUP,3} ES HIDROGENO, ALQUILO C{SUB,1}-C{SUB,6}, HALOGENO, ALCOXI C{SUB,1}-C{SUB,6}, TRIFLUOROALQUILO O TRIFLUOROALCOXI; B ES (E), (F) O (G), DONDE R{SUP,4} ES HIDROGENO, ALQUILO C{SUB,1}-C{SUB,6}, ALILO, ARILO C{SUB,1}C{SUB,6}, ARIL-(CH{SUB,2}){SUB,1-6}-, FLUORO, CLORO, BROMO, IODO, TRIMETILSILIL O CICLOALQUILO C{SUB,3}-C{SUB,8}; R{SUP,5} ES HIDROGENO, ALQUILO C{SUB,1}-C{SUB,6},ARILO C{SUB,1}-C{SUB,6}, ARIL-(CH{SUB,2}){SUB,1-6}-; M ES 0, 1 O 2; R{SUP,6} ES HIDROGENO O ALQUILO C{SUB,1}-C{SUB,6}; R{SUP,7} ES HIDROGENO O ALQUILO C{SUB,1}-C{SUB,6}; R{SUP,8} Y R{SUP,9} SON SELECCIONADOS INDEPENDIENTEMENTE DE HIDROGENO, ALQUILO C{SUB,1}-C{SUB,6}, FLUORO, CLORO, BROMO O IODO; Y ES O O S; Z ES N O CH CUANDO Y ES O Y Z ES CH CUANDO Y ES S; TAMBIEN SE REIVINDICAN SUS SALES FARMACEUTICAMENTE ACEPTABLES.
ES95916989T 1994-05-18 1995-04-13 Azolidindionas como agentes antihiperglucemicos. Expired - Lifetime ES2124545T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/245,734 US5468762A (en) 1994-05-18 1994-05-18 Azolidinediones as antihyperglycemic agents

Publications (1)

Publication Number Publication Date
ES2124545T3 true ES2124545T3 (es) 1999-02-01

Family

ID=22927868

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95916989T Expired - Lifetime ES2124545T3 (es) 1994-05-18 1995-04-13 Azolidindionas como agentes antihiperglucemicos.

Country Status (17)

Country Link
US (2) US5468762A (es)
EP (1) EP0759919B1 (es)
JP (1) JPH10500133A (es)
KR (1) KR970703340A (es)
CN (1) CN1152312A (es)
AT (1) ATE173256T1 (es)
AU (1) AU684357B2 (es)
CA (1) CA2190015A1 (es)
DE (1) DE69505968T2 (es)
DK (1) DK0759919T3 (es)
ES (1) ES2124545T3 (es)
GR (1) GR3029355T3 (es)
HU (1) HUT76823A (es)
NZ (1) NZ284654A (es)
TW (1) TW328089B (es)
WO (1) WO1995031454A1 (es)
ZA (1) ZA953981B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728720A (en) * 1993-12-27 1998-03-17 Japan Tobacco Inc. Isoxazolidinedione compounds and use thereof
ATE235476T1 (de) * 1994-08-10 2003-04-15 Takeda Chemical Industries Ltd Thiazolidindione derivate, ihre herstellung und verwendung
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
CA2171702A1 (en) * 1995-03-14 1996-09-15 Takashi Sohda Benzofuran compounds and their use
US5925656A (en) * 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5889032A (en) * 1996-05-06 1999-03-30 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6372750B2 (en) * 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
CA2258949C (en) 1996-07-01 2008-05-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6011036A (en) * 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
US6011031A (en) * 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
AU6331199A (en) * 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Oxazolidine derivatives for the treatment and prevention of metabolic bone disorders
US6756360B1 (en) 1998-12-24 2004-06-29 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
AU6875800A (en) * 1999-09-10 2001-04-17 Takeda Chemical Industries Ltd. Heterocyclic compounds and process for the preparation thereof
WO2001047935A2 (en) * 1999-12-22 2001-07-05 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
US7563774B2 (en) * 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
EP1442028A4 (en) * 2001-11-06 2009-11-04 Bristol Myers Squibb Co SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
US7351726B2 (en) * 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
CN101005847A (zh) * 2004-08-18 2007-07-25 症变治疗公司 果糖1,6－双磷酸酶的新颖噻唑类抑制剂
AU2013340478B2 (en) 2012-11-05 2018-08-23 Commissariat A L'energie Atomique Et Aux Energies Alternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a STAT5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5334604A (en) * 1990-08-23 1994-08-02 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
FR2673427B1 (fr) * 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
TW268952B (es) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd

Also Published As

Publication number Publication date
EP0759919B1 (en) 1998-11-11
DK0759919T3 (da) 1999-07-26
AU2384295A (en) 1995-12-05
EP0759919A1 (en) 1997-03-05
HUT76823A (en) 1997-11-28
NZ284654A (en) 1998-12-23
CN1152312A (zh) 1997-06-18
US5468762A (en) 1995-11-21
ATE173256T1 (de) 1998-11-15
KR970703340A (ko) 1997-07-03
JPH10500133A (ja) 1998-01-06
ZA953981B (en) 1996-11-18
WO1995031454A1 (en) 1995-11-23
HU9603185D0 (en) 1997-01-28
GR3029355T3 (en) 1999-05-28
TW328089B (en) 1998-03-11
DE69505968T2 (de) 1999-05-12
CA2190015A1 (en) 1995-11-23
DE69505968D1 (de) 1998-12-17
AU684357B2 (en) 1997-12-11
US5510360A (en) 1996-04-23

Similar Documents

Publication Publication Date Title
ES2124545T3 (es) Azolidindionas como agentes antihiperglucemicos.
KR950701911A (ko) 피페리딘 유도체를 유효성분으로 하는 말초혈관확장제(peripheral vaso-dilating agent containing piperidine derivative as active ingredient)
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
MX9709951A (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
ES2166359T3 (es) Derivado de depsipeptido, su produccion y uso.
ES2141174T3 (es) 4-arilmetiloximetil piperidinas como antagonistas de taquiquinina.
AR031031A1 (es) Composicion pesticida
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
DE69111619T2 (de) 1,4-benzothiazedinderivat.
GB9408185D0 (en) New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
DK0640601T3 (da) Benzamidderivat
NO982873D0 (no) 1-metylkarbapenemderivater
ES2191341T3 (es) Derivados de la 2-fenoxianilina.
EP0552489A3 (es)
DK0420224T3 (da) Anthihepatopatisk middel
ES2058458T3 (es) Inhibidor de la formacion de la placa dental.
ATE144900T1 (de) Verwendung von xanthinderivaten gegen magengeschwüre
ECSP951498A (es) Nuevos derivados de pirrocarbazol case ran 4121/15
ATE44741T1 (de) 2-(n-substituierte guanidino)-4heteroarylthiazole als mittel gegen geschwuere.
DE3782229T2 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
TW360630B (en) A secoaporphine compounds on arrhythmia

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 759919

Country of ref document: ES